Xbrane Biopharma AB Cash Flow Conversion Efficiency

Latest as of June 2026: -0.009x

Xbrane Biopharma AB cash flow conversion efficiency. Based on the latest financial reports, Xbrane Biopharma AB (XBRANE) has a cash flow conversion efficiency ratio of -0.009x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-4.82 Million ≈ $-518.82K USD) by net assets (Skr538.85 Million ≈ $57.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Xbrane Biopharma AB (2013–2025)

Cash flow conversion efficiency of Xbrane Biopharma AB from 2013 to 2025. This chart illustrates how Xbrane Biopharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Xbrane Biopharma AB share price for real-time trading data and today's change.

Xbrane Biopharma AB Cash Flow Conversion Ratio Explained

Xbrane Biopharma AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Xbrane Biopharma AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Xbrane Biopharma AB ranked by their cash flow conversion efficiency. Also see XBRANE stock market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Tecom Co Ltd TW:2321	-0.015x
CZR Resources Ltd AU:CZR	-0.033x
Dunia Virtual Online Tbk Pt JK:AREA	0.063x
Lyka Labs Limited NSE:LYKALABS	0.135x
Gadang Holdings Bhd KLSE:9261	0.000x
Intrum Justitia AB ST:INTRUM	0.059x
Konsortium Transnasional Bhd KLSE:4847	0.060x
Sung Bo Chem KO:003080	-0.044x

Annual Cash Flow Conversion Efficiency for Xbrane Biopharma AB (2013–2025)

The table below shows the annual cash flow conversion efficiency of Xbrane Biopharma AB from 2013 to 2025. Review free cash flow generation of Xbrane Biopharma AB to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr560.65 Million ≈ $60.34 Million	Skr-250.69 Million ≈ $-26.98 Million	-0.447x	+30.27%
2024-12-31	Skr208.54 Million ≈ $22.44 Million	Skr-133.73 Million ≈ $-14.39 Million	-0.641x	+72.98%
2023-12-31	Skr171.34 Million ≈ $18.44 Million	Skr-406.68 Million ≈ $-43.77 Million	-2.374x	-420.07%
2022-12-31	Skr424.89 Million ≈ $45.72 Million	Skr-193.92 Million ≈ $-20.87 Million	-0.456x	+10.27%
2021-12-31	Skr431.74 Million ≈ $46.46 Million	Skr-219.61 Million ≈ $-23.63 Million	-0.509x	+45.02%
2020-12-31	Skr257.71 Million ≈ $27.73 Million	Skr-238.41 Million ≈ $-25.66 Million	-0.925x	-14.76%
2019-12-31	Skr184.32 Million ≈ $19.84 Million	Skr-148.59 Million ≈ $-15.99 Million	-0.806x	-243.37%
2018-12-31	Skr83.07 Million ≈ $8.94 Million	Skr46.71 Million ≈ $5.03 Million	0.562x	+234.89%
2017-12-31	Skr88.41 Million ≈ $9.51 Million	Skr-36.85 Million ≈ $-3.97 Million	-0.417x	-13.44%
2016-12-31	Skr107.30 Million ≈ $11.55 Million	Skr-39.43 Million ≈ $-4.24 Million	-0.367x	-40.93%
2015-12-31	Skr47.51 Million ≈ $5.11 Million	Skr-12.39 Million ≈ $-1.33 Million	-0.261x	+38.46%
2014-12-31	Skr6.30 Million ≈ $677.75K	Skr-2.67 Million ≈ $-287.16K	-0.424x	-67.55%
2013-12-31	Skr8.69 Million ≈ $935.17K	Skr-2.20 Million ≈ $-236.48K	-0.253x	--

About Xbrane Biopharma AB

ST:XBRANE Sweden Biotechnology

Market Cap

$29.16 Million

Skr270.96 Million SEK

Market Cap Rank

#23677 Global

#447 in Sweden

Share Price

Skr13.15

Change (1 day)

+1.15%

52-Week Range

Skr5.66 - Skr17.40

All Time High

Skr176.00